X4 Pharmaceuticals (XFOR) Competitors $0.19 0.00 (-2.30%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$0.20 +0.01 (+7.44%) As of 04/17/2025 06:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock XFOR vs. FULC, DERM, ACRS, IPHA, MOLN, PBYI, KRRO, CTNM, RAPT, and TNGXShould you be buying X4 Pharmaceuticals stock or one of its competitors? The main competitors of X4 Pharmaceuticals include Fulcrum Therapeutics (FULC), Journey Medical (DERM), Aclaris Therapeutics (ACRS), Innate Pharma (IPHA), Molecular Partners (MOLN), Puma Biotechnology (PBYI), Korro Bio (KRRO), Contineum Therapeutics (CTNM), RAPT Therapeutics (RAPT), and Tango Therapeutics (TNGX). These companies are all part of the "pharmaceutical products" industry. X4 Pharmaceuticals vs. Fulcrum Therapeutics Journey Medical Aclaris Therapeutics Innate Pharma Molecular Partners Puma Biotechnology Korro Bio Contineum Therapeutics RAPT Therapeutics Tango Therapeutics X4 Pharmaceuticals (NASDAQ:XFOR) and Fulcrum Therapeutics (NASDAQ:FULC) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, earnings, institutional ownership, media sentiment, profitability, community ranking, dividends and analyst recommendations. Does the media prefer XFOR or FULC? In the previous week, X4 Pharmaceuticals and X4 Pharmaceuticals both had 1 articles in the media. Fulcrum Therapeutics' average media sentiment score of 1.17 beat X4 Pharmaceuticals' score of 0.00 indicating that Fulcrum Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment X4 Pharmaceuticals Neutral Fulcrum Therapeutics Positive Do institutionals and insiders believe in XFOR or FULC? 72.0% of X4 Pharmaceuticals shares are held by institutional investors. Comparatively, 89.8% of Fulcrum Therapeutics shares are held by institutional investors. 1.6% of X4 Pharmaceuticals shares are held by company insiders. Comparatively, 4.1% of Fulcrum Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Do analysts recommend XFOR or FULC? X4 Pharmaceuticals currently has a consensus price target of $2.83, indicating a potential upside of 1,384.98%. Fulcrum Therapeutics has a consensus price target of $8.63, indicating a potential upside of 162.16%. Given X4 Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe X4 Pharmaceuticals is more favorable than Fulcrum Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score X4 Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Fulcrum Therapeutics 1 Sell rating(s) 6 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.11 Is XFOR or FULC more profitable? Fulcrum Therapeutics' return on equity of -7.31% beat X4 Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets X4 PharmaceuticalsN/A -236.19% -75.14% Fulcrum Therapeutics N/A -7.31%-6.74% Does the MarketBeat Community prefer XFOR or FULC? Fulcrum Therapeutics received 19 more outperform votes than X4 Pharmaceuticals when rated by MarketBeat users. However, 68.10% of users gave X4 Pharmaceuticals an outperform vote while only 60.87% of users gave Fulcrum Therapeutics an outperform vote. CompanyUnderperformOutperformX4 PharmaceuticalsOutperform Votes7968.10% Underperform Votes3731.90% Fulcrum TherapeuticsOutperform Votes9860.87% Underperform Votes6339.13% Which has more volatility & risk, XFOR or FULC? X4 Pharmaceuticals has a beta of 0.58, meaning that its stock price is 42% less volatile than the S&P 500. Comparatively, Fulcrum Therapeutics has a beta of 2.13, meaning that its stock price is 113% more volatile than the S&P 500. Which has better earnings & valuation, XFOR or FULC? Fulcrum Therapeutics has higher revenue and earnings than X4 Pharmaceuticals. Fulcrum Therapeutics is trading at a lower price-to-earnings ratio than X4 Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioX4 Pharmaceuticals$2.56M12.96-$101.17M-$0.19-1.00Fulcrum Therapeutics$80M2.22-$97.33M-$0.22-14.95 SummaryFulcrum Therapeutics beats X4 Pharmaceuticals on 9 of the 16 factors compared between the two stocks. Get X4 Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for XFOR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart XFOR vs. The Competition Export to ExcelMetricX4 PharmaceuticalsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$33.14M$2.84B$5.30B$7.35BDividend YieldN/A1.86%5.45%4.30%P/E Ratio-2.1230.4821.8617.81Price / Sales12.96441.91380.6697.70Price / CashN/A168.6838.2634.64Price / Book0.623.466.453.98Net Income-$101.17M-$72.06M$3.22B$247.81M1 Month Performance-36.32%-16.76%-9.75%-7.92%1 Year Performance-84.86%-26.05%11.50%1.52% X4 Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)XFORX4 Pharmaceuticals4.2747 of 5 stars$0.19-2.3%$2.83+1,385.0%-84.1%$33.14M$2.56M-2.1280FULCFulcrum Therapeutics2.2479 of 5 stars$2.72+8.4%$8.63+217.1%-53.4%$146.82M$80M-8.77100Short Interest ↓News CoveragePositive NewsDERMJourney Medical2.2925 of 5 stars$6.96-3.2%$9.88+41.9%+74.6%$145.39M$56.13M-7.4090Short Interest ↑High Trading VolumeACRSAclaris Therapeutics1.8263 of 5 stars$1.33-5.0%$11.67+777.2%-7.3%$143.53M$18.72M-2.56100IPHAInnate Pharma1.9708 of 5 stars$1.71-6.6%$11.50+572.5%-17.9%$143.35M$12.63M0.00220Gap DownMOLNMolecular Partners1.6018 of 5 stars$3.54-0.8%$12.00+239.0%+6.1%$142.93M$4.97M-1.65180PBYIPuma Biotechnology3.3331 of 5 stars$2.83-2.4%$7.00+147.3%-42.7%$140.40M$230.47M5.90200Analyst UpgradeKRROKorro Bio1.3682 of 5 stars$14.93+3.8%$136.33+813.2%-79.2%$140.18M$2.27M-1.5970Analyst ForecastNews CoveragePositive NewsGap UpCTNMContineum Therapeutics2.1698 of 5 stars$5.37-7.4%$24.80+361.8%-70.2%$138.93M$50M-1.1031Gap UpRAPTRAPT Therapeutics3.6137 of 5 stars$1.05-0.9%$4.00+281.0%-90.0%$138.61M$1.53M-0.3880Short Interest ↑News CoverageTNGXTango Therapeutics1.9171 of 5 stars$1.27flat$12.33+871.1%-82.5%$137.30M$42.07M-1.0890Analyst RevisionNews Coverage Related Companies and Tools Related Companies FULC Competitors DERM Competitors ACRS Competitors IPHA Competitors MOLN Competitors PBYI Competitors KRRO Competitors CTNM Competitors RAPT Competitors TNGX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:XFOR) was last updated on 4/19/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredThe Crypto Market is About to Change LivesI've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding X4 Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share X4 Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy XFOR Stock Free XFOR Stock Alerts